Literature DB >> 8202160

cMpl ligand is a humoral regulator of megakaryocytopoiesis.

F Wendling1, E Maraskovsky, N Debili, C Florindo, M Teepe, M Titeux, N Methia, J Breton-Gorius, D Cosman, W Vainchenker.   

Abstract

Megakaryocytopoiesis is the cellular developmental process that leads to platelet production. At least two humoral growth factors may be necessary for megakaryocyte proliferation and maturation. One is a megakaryocyte-colony stimulating factor (MK-CSF) which induces the proliferation and differentiation of megakaryocyte progenitors, and the second, thrombopoietin, is a megakaryocyte maturation factor. Neither of these factors has been fully characterized. The proto-oncogene c-mpl, an orphan member of the haematopoietin receptor family, is specifically involved in megakaryocyte regulation. Here we present evidence that the c-mpl-encoded receptor binds a ligand (c-Mpl ligand) which is a humoral factor implicated in platelet homeostasis. Our results suggest that c-Mpl ligand, thrombopoietin and MK-CSF might be the same molecule.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8202160     DOI: 10.1038/369571a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  70 in total

Review 1.  Primary thrombocytosis in children.

Authors:  Nicole Kucine; Katherine M Chastain; Michelle B Mahler; James B Bussel
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

Review 2.  Hematopoietic cytokines.

Authors:  Donald Metcalf
Journal:  Blood       Date:  2008-01-15       Impact factor: 22.113

3.  Inhibition of GSK-3beta promotes survival and proliferation of megakaryocytic cells through a beta-catenin-independent pathway.

Authors:  Mie Soda; Karl Willert; Kenneth Kaushansky; Amy E Geddis
Journal:  Cell Signal       Date:  2008-09-06       Impact factor: 4.315

4.  Targeted expansion of genetically modified bone marrow cells.

Authors:  L Jin; N Siritanaratkul; D W Emery; R E Richard; K Kaushansky; T Papayannopoulou; C A Blau
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

Review 5.  Thrombopoietin and platelet development.

Authors:  K Kaushansky
Journal:  West J Med       Date:  1996-03

6.  Adenovirus-mediated transfer of the HST-1 (FGF4) gene induces increased levels of platelet count in vivo.

Authors:  H Sakamoto; T Ochiya; Y Sato; M Tsukamoto; H Konishi; I Saito; T Sugimura; M Terada
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

7.  Constitutive activation of a variant of the env-mpl oncogene product by disulfide-linked homodimerization.

Authors:  G Courtois; L Bénit; Y Mikaeloff; M Pauchard; M Charon; P Varlet; S Gisselbrecht
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

Review 8.  Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.

Authors:  Roberto Stasi; Maria L Evangelista; Sergio Amadori
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents.

Authors:  Ara Metjian; Charles S Abrams
Journal:  Biologics       Date:  2009-12-29

10.  Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.

Authors:  Connie L Erickson-Miller; Evelyne Delorme; Shin-Shay Tian; Christopher B Hopson; Amy J Landis; Elizabeth I Valoret; Teresa S Sellers; Jon Rosen; Stephen G Miller; Juan I Luengo; Kevin J Duffy; Julian M Jenkins
Journal:  Stem Cells       Date:  2009-02       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.